{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:03Z","timestamp":1775872263071,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"DOI":"10.7759\/cureus.103314","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:09:34Z","timestamp":1770689374000},"source":"Crossref","is-referenced-by-count":1,"title":["Moxifloxacin-Induced Peripheral Neuropathy: A Rare Side Effect of Fluoroquinolone Therapy in Tuberculosis Management"],"prefix":"10.7759","author":[{"given":"Dillon","family":"Prus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lenox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.05.003","article-title":"Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis","volume":"60","author":"Xu P","year":"2017","unstructured":"Xu P, Chen H, Xu J, et al.. Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. Int J Infect Dis. 2017, 60:35-41. 10.1016\/j.ijid.2017.05.003","journal-title":"Int J Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022","volume":"71","author":"Carr W","year":"2022","unstructured":"Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022, 71:285-9. 10.15585\/mmwr.mm7108a1","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman SE","year":"2021","unstructured":"Dorman SE, Nahid P, Kurbatova EV, et al.. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021, 384:1705-18. 10.1056\/NEJMoa2033400","journal-title":"N Engl J Med"},{"key":"ref4","article-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","year":"2012","unstructured":"LiverTox. Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2012."},{"key":"ref5","unstructured":"FDA drug safety communication. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. (2016). Accessed: September 16, 2025: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-in...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2015.11.002","article-title":"Peripheral neuropathy in persons with tuberculosis","volume":"2","author":"Mafukidze AT","year":"2016","unstructured":"Mafukidze AT, Calnan M, Furin J. Peripheral neuropathy in persons with tuberculosis. J Clin Tuberc Other Mycobact Dis. 2016, 2:5-11. 10.1016\/j.jctube.2015.11.002","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie F","year":"2022","unstructured":"Conradie F, Bagdasaryan TR, Borisov S, et al.. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022, 387:810-23. 10.1056\/NEJMoa2119430","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0887","article-title":"Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy","volume":"76","author":"Morales D","year":"2019","unstructured":"Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. Association between peripheral neuropathy and exposure to oral fluoroquinolone or amoxicillin-clavulanate therapy. JAMA Neurol. 2019, 76:827-33. 10.1001\/jamaneurol.2019.0887","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1713170","article-title":"Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database","volume":"16","author":"He Y","year":"2025","unstructured":"He Y, Liang L, Wei S. Comparative safety profile of levofloxacin versus moxifloxacin in first-line tuberculosis therapy: a pharmacovigilance study of the FAERS database. Front Pharmacol. 2025, 16:1713170. 10.3389\/fphar.2025.1713170","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al..  A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86248","article-title":"Characterizing musculoskeletal and neurological toxicities associated with the BPaLM regimen: a clinical evaluation of arthralgia and peripheral neuropathy in patients with multidrug-resistant tuberculosis (MDR-TB)","volume":"17","author":"Khan Z","year":"2025","unstructured":"Khan Z, Ali G, Rumman, et al.. Characterizing musculoskeletal and neurological toxicities associated with the BPaLM regimen: a clinical evaluation of arthralgia and peripheral neuropathy in patients with multidrug-resistant tuberculosis (MDR-TB). Cureus. 2025, 17:e86248. 10.7759\/cureus.86248","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2499-1","article-title":"Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature","volume":"17","author":"Swaminathan A","year":"2017","unstructured":"Swaminathan A, du Cros P, Seddon JA, Mirgayosieva S, Asladdin R, Dusmatova Z. Peripheral neuropathy in a diabetic child treated with linezolid for multidrug-resistant tuberculosis: a case report and review of the literature. BMC Infect Dis. 2017, 17:417. 10.1186\/s12879-017-2499-1","journal-title":"BMC Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000489303","article-title":"Severe acute axonal neuropathy induced by ciprofloxacin: a case report","volume":"10","author":"Popescu C","year":"2018","unstructured":"Popescu C. Severe acute axonal neuropathy induced by ciprofloxacin: a case report. Case Rep Neurol. 2018, 10:124-9. 10.1159\/000489303","journal-title":"Case Rep Neurol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky793","article-title":"Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of topoisomerase 2","volume":"46","author":"Hangas A","year":"2018","unstructured":"Hangas A, Aasumets K, Kek\u00e4l\u00e4inen NJ, Palohein\u00e4 M, Pohjoism\u00e4ki JL, Gerhold JM, Goffart S. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of topoisomerase 2. Nucleic Acids Res. 2018, 46:9625-36. 10.1093\/nar\/gky793","journal-title":"Nucleic Acids Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420932-moxifloxacin-induced-peripheral-neuropathy-a-rare-side-effect-of-fluoroquinolone-therapy-in-tuberculosis-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T02:09:36Z","timestamp":1770689376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420932-moxifloxacin-induced-peripheral-neuropathy-a-rare-side-effect-of-fluoroquinolone-therapy-in-tuberculosis-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.103314","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,9]]}}}